vs
Side-by-side financial comparison of Phathom Pharmaceuticals, Inc. (PHAT) and SITIME Corp (SITM). Click either name above to swap in a different company.
SITIME Corp is the larger business by last-quarter revenue ($113.6M vs $57.6M, roughly 2.0× Phathom Pharmaceuticals, Inc.). On growth, Phathom Pharmaceuticals, Inc. posted the faster year-over-year revenue change (94.1% vs 88.3%).
Phathom Pharmaceuticals is a clinical-stage biopharmaceutical firm focused on developing and commercializing innovative therapies for gastrointestinal diseases. Its lead product candidates address acid-related disorders, inflammatory bowel disease, and other GI conditions, serving patients mainly across North America and Europe.
SiTime Corporation is a publicly traded fabless chipmaker based in Santa Clara, California that develops micro-electromechanical systems (MEMS), used for timing devices in electronics.
PHAT vs SITM — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $57.6M | $113.6M |
| Net Profit | — | — |
| Gross Margin | 86.7% | 59.0% |
| Operating Margin | — | 30.2% |
| Net Margin | — | — |
| Revenue YoY | 94.1% | 88.3% |
| Net Profit YoY | 71.6% | — |
| EPS (diluted) | — | $-0.20 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $113.6M | ||
| Q4 25 | $57.6M | $113.3M | ||
| Q3 25 | $49.5M | $83.6M | ||
| Q2 25 | $39.5M | $69.5M | ||
| Q1 25 | $28.5M | $60.3M | ||
| Q4 24 | $29.7M | $68.1M | ||
| Q3 24 | $16.4M | $57.7M | ||
| Q2 24 | $7.3M | $43.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | $9.2M | ||
| Q3 25 | $-30.0M | $-8.0M | ||
| Q2 25 | $-75.8M | $-20.2M | ||
| Q1 25 | $-94.3M | $-23.9M | ||
| Q4 24 | — | $-18.8M | ||
| Q3 24 | $-85.6M | $-19.3M | ||
| Q2 24 | $-91.4M | $-26.8M |
| Q1 26 | — | 59.0% | ||
| Q4 25 | 86.7% | 56.4% | ||
| Q3 25 | 87.5% | 53.5% | ||
| Q2 25 | 87.2% | 51.9% | ||
| Q1 25 | 86.9% | 50.3% | ||
| Q4 24 | 87.1% | 52.6% | ||
| Q3 24 | 85.6% | 51.1% | ||
| Q2 24 | 81.2% | 49.1% |
| Q1 26 | — | 30.2% | ||
| Q4 25 | — | 1.6% | ||
| Q3 25 | -30.8% | -19.2% | ||
| Q2 25 | -151.7% | -35.4% | ||
| Q1 25 | -276.5% | -46.6% | ||
| Q4 24 | — | -33.8% | ||
| Q3 24 | -433.0% | -43.1% | ||
| Q2 24 | -1055.4% | -73.7% |
| Q1 26 | — | — | ||
| Q4 25 | — | 8.1% | ||
| Q3 25 | -60.5% | -9.6% | ||
| Q2 25 | -191.9% | -29.0% | ||
| Q1 25 | -330.7% | -39.6% | ||
| Q4 24 | — | -27.6% | ||
| Q3 24 | -523.3% | -33.5% | ||
| Q2 24 | -1248.6% | -61.0% |
| Q1 26 | — | $-0.20 | ||
| Q4 25 | — | $0.44 | ||
| Q3 25 | $-0.41 | $-0.31 | ||
| Q2 25 | $-1.05 | $-0.84 | ||
| Q1 25 | $-1.31 | $-1.01 | ||
| Q4 24 | — | $-0.80 | ||
| Q3 24 | $-1.32 | $-0.83 | ||
| Q2 24 | $-1.56 | $-1.16 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $130.0M | $498.5M |
| Total DebtLower is stronger | $209.1M | — |
| Stockholders' EquityBook value | $-438.2M | $1.2B |
| Total Assets | $259.1M | $1.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $498.5M | ||
| Q4 25 | $130.0M | — | ||
| Q3 25 | $135.2M | — | ||
| Q2 25 | $149.6M | — | ||
| Q1 25 | $212.3M | — | ||
| Q4 24 | $297.3M | — | ||
| Q3 24 | $334.7M | — | ||
| Q2 24 | $276.2M | — |
| Q1 26 | — | — | ||
| Q4 25 | $209.1M | — | ||
| Q3 25 | $207.1M | — | ||
| Q2 25 | $205.1M | — | ||
| Q1 25 | $203.2M | — | ||
| Q4 24 | $201.4M | — | ||
| Q3 24 | $175.7M | — | ||
| Q2 24 | $174.4M | — |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $-438.2M | $1.2B | ||
| Q3 25 | $-422.5M | $1.1B | ||
| Q2 25 | $-405.8M | $1.1B | ||
| Q1 25 | $-338.4M | $692.5M | ||
| Q4 24 | $-253.6M | $699.7M | ||
| Q3 24 | $-187.1M | $696.2M | ||
| Q2 24 | $-233.8M | $692.5M |
| Q1 26 | — | $1.3B | ||
| Q4 25 | $259.1M | $1.3B | ||
| Q3 25 | $240.3M | $1.3B | ||
| Q2 25 | $250.2M | $1.3B | ||
| Q1 25 | $294.2M | $872.1M | ||
| Q4 24 | $378.3M | $885.0M | ||
| Q3 24 | $387.0M | $877.9M | ||
| Q2 24 | $319.4M | $878.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-166.8M | — |
| Free Cash FlowOCF − Capex | $-167.0M | — |
| FCF MarginFCF / Revenue | -290.0% | — |
| Capex IntensityCapex / Revenue | 0.4% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-328.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-166.8M | $25.4M | ||
| Q3 25 | $-14.1M | $31.4M | ||
| Q2 25 | $-62.7M | $15.3M | ||
| Q1 25 | $-84.9M | $15.0M | ||
| Q4 24 | $-266.8M | $13.5M | ||
| Q3 24 | $-63.6M | $8.2M | ||
| Q2 24 | $-70.7M | $-181.0K |
| Q1 26 | — | — | ||
| Q4 25 | $-167.0M | $13.0M | ||
| Q3 25 | $-14.1M | $26.3M | ||
| Q2 25 | $-62.8M | $-2.9M | ||
| Q1 25 | $-84.9M | $-1.3M | ||
| Q4 24 | $-266.9M | $-2.4M | ||
| Q3 24 | $-63.6M | $-6.7M | ||
| Q2 24 | $-70.8M | $-2.7M |
| Q1 26 | — | — | ||
| Q4 25 | -290.0% | 11.5% | ||
| Q3 25 | -28.6% | 31.5% | ||
| Q2 25 | -159.0% | -4.2% | ||
| Q1 25 | -297.9% | -2.1% | ||
| Q4 24 | -899.8% | -3.5% | ||
| Q3 24 | -389.0% | -11.6% | ||
| Q2 24 | -966.2% | -6.3% |
| Q1 26 | — | — | ||
| Q4 25 | 0.4% | 10.9% | ||
| Q3 25 | 0.1% | 6.1% | ||
| Q2 25 | 0.2% | 26.2% | ||
| Q1 25 | 0.1% | 27.0% | ||
| Q4 24 | 0.5% | 23.3% | ||
| Q3 24 | 0.3% | 25.7% | ||
| Q2 24 | 0.6% | 5.8% |
| Q1 26 | — | — | ||
| Q4 25 | — | 2.77× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
